{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:40:10Z","timestamp":1793176810678,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2023.11.012","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T12:04:48Z","timestamp":1700827488000},"page":"295-304.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-3480","authenticated-orcid":false,"given":"Laurence","family":"Albig\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-4671","authenticated-orcid":false,"given":"Carine","family":"Bellera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Branchoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-1833","authenticated-orcid":false,"given":"Amandine","family":"Gouverneur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"N\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Fran\u00e7oise","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4078-1476","authenticated-orcid":false,"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"N\u00e9grier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2023.11.012_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clgc.2023.11.012_bib0002","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.11.012_bib0003","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12885-021-08261-1","article-title":"Cancer incidence and mortality trends in France over 1990-2018 for solid tumors: the sex gap is narrowing","volume":"21","author":"Defossez","year":"2021","journal-title":"BMC Cancer"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2023.11.012_bib0004","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2023.11.012_bib0005","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.annonc.2021.09.014","article-title":"ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2023.11.012_bib0006","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.11.012_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jgo.2017.08.001","article-title":"Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: a systematic review","volume":"9","author":"Gouverneur","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2023.11.012_bib0008","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0300891618761004","article-title":"Real-world evidence in metastatic renal cell carcinoma","volume":"104","author":"Graham","year":"2018","journal-title":"Tumori J"},{"issue":"6","key":"10.1016\/j.clgc.2023.11.012_bib0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JOP.2015.004929","article-title":"Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice","volume":"11","author":"Mitchell","year":"2015","journal-title":"J Oncol Pract"},{"issue":"8","key":"10.1016\/j.clgc.2023.11.012_bib0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2217\/fon-2020-0951","article-title":"Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer","volume":"17","author":"Nazha","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2023.11.012_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803935","article-title":"Real-world metastatic renal cell carcinoma treatment patterns and clinical outcomes in The Netherlands","volume":"13","author":"van Laar","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.clgc.2023.11.012_bib0012","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1016\/j.clgc.2019.05.017","article-title":"Real-world evidence data on metastatic renal-cell carcinoma treatment in Austria: the RELACS study","volume":"17","author":"Schmidinger","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2023.11.012_bib0013","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s12885-022-09694-y","article-title":"Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study","volume":"22","author":"Waddell","year":"2022","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2023.11.012_bib0014","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/03007995.2017.1360850","article-title":"Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database","volume":"33","author":"Maroun","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.clgc.2023.11.012_bib0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12885-018-4117-z","article-title":"Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data","volume":"18","author":"Maroun","year":"2018","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2023.11.012_bib0016","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/pds.4228","article-title":"Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study","volume":"26","author":"Noize","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.clgc.2023.11.012_bib0017","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4149\/neo_2020_200512N519","article-title":"Real-world safety and efficacy of nivolumab for \u2265 2nd line treatment of metastatic renal cell carcinoma: a retrospective cohort study in Croatia, Hungary, and Malta","volume":"68","author":"Vrdoljak","year":"2021","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.clgc.2023.11.012_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2021.07.002","article-title":"A prospective multicenter evaluation of initial treatment choice in metastatic renal cell carcinoma prior to the immunotherapy era: the MaRCC registry experience","volume":"20","author":"Costello","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"22","key":"10.1016\/j.clgc.2023.11.012_bib0019","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1002\/cncr.32383","article-title":"Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer","volume":"125","author":"Khozin","year":"2019","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2023.11.012_bib0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.eururo.2019.07.048","article-title":"First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium","volume":"76","author":"Dudani","year":"2019","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.clgc.2023.11.012_bib0021","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.clgc.2023.11.012_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100340","article-title":"Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial","volume":"7","author":"Branchoux","year":"2021","journal-title":"ESMO Open"},{"issue":"suppl 7","key":"10.1016\/j.clgc.2023.11.012_bib0023","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2019.37.7_suppl.542","article-title":"Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): final analysis from the NIVOREN GETUG AFU 26 study","volume":"37","author":"Albiges","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.11.012_bib0024","doi-asserted-by":"crossref","first-page":"S697","DOI":"10.1016\/j.annonc.2021.08.070","article-title":"674P WITNESS: real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline","volume":"32","author":"Thiery-Vuillemin","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2023.11.012_bib0025","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/j.clgc.2017.09.006","article-title":"Factors influencing overall survival for patients with metastatic clear-cell renal-cell carcinoma in daily practice","volume":"16","author":"Thiery-Vuillemin","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2023.11.012_bib0026","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.respe.2017.03.132","article-title":"Agreement between hospital discharge diagnosis codes and medical records to identify metastatic colorectal cancer and associated comorbidities in elderly patients","volume":"65","author":"Gouverneur","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"1","key":"10.1016\/j.clgc.2023.11.012_bib0027","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"suppl 12","key":"10.1016\/j.clgc.2023.11.012_bib0028","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1166-7087(20)30749-1","article-title":"[French ccAFU guidelines - update 2020-2022: management of kidney cancer]","volume":"30","author":"Bensalah","year":"2020","journal-title":"Prog Urol"},{"issue":"19","key":"10.1016\/j.clgc.2023.11.012_bib0029","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clgc.2023.11.012_bib0030","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2023.11.012_bib0031","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.critrevonc.2017.11.009","article-title":"Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma","volume":"121","author":"Climent","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"22","key":"10.1016\/j.clgc.2023.11.012_bib0032","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clgc.2023.11.012_bib0033","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2023.11.012_bib0034","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1634\/theoncologist.2019-0605","article-title":"Real-world assessment of clinical outcomes among first-line sunitinib patients with clear cell metastatic renal cell carcinoma (mRCC) by the International mRCC Database Consortium Risk Group","volume":"25","author":"Savard","year":"2020","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.clgc.2023.11.012_bib0037","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.clgc.2023.11.012_bib0038","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.semnephrol.2019.12.009","article-title":"Immune checkpoint inhibitors in the treatment of renal cell carcinoma","volume":"40","author":"Parikh","year":"2020","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.clgc.2023.11.012_bib0039","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","article-title":"Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events","volume":"157","author":"Kostine","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732300263X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732300263X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:28:41Z","timestamp":1793176121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732300263X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S155876732300263X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.11.012","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}